(function(){var loadHandler=window['sl_{70F84434-E230-4897-A900-6C791B0E8453}'];loadHandler&&loadHandler(4, '<div id="spr0_52e6ccbe"><div id="spr1_52e6ccbe" class="kern slide"><img id="img4_52e6ccbe" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_52e6ccbe" class="kern slide"><img id="img0_52e6ccbe" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_52e6ccbe" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_52e6ccbe" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_52e6ccbe" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_52e6ccbe" style="left:657.715px;top:499.855px;"><img id="img2_52e6ccbe" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_52e6ccbe" style="left:-1.48px;top:8.914px;"><div style="width:0px;"><span id="txt0_52e6ccbe" data-width="506.015625" style="left:107.8px;top:5.086px;">2016 CCS Lipid Guidelines Recommend:</span></div><div style="width:0px;"><span id="txt1_52e6ccbe" data-width="605.031250" style="left:58.655px;top:43.486px;">Recommendations for PCSK9i in FH and ASCVD</span></div></div><div id="spr5_52e6ccbe" style="left:19.805px;top:164.544px;"><div style="width:0px;"><span id="txt2_52e6ccbe" data-width="189.472656" style="left:69.38px;top:6.231px;">TREATMENT TARGETS:</span></div></div><div id="spr6_52e6ccbe" style="left:210px;top:90.456px;"><img id="img3_52e6ccbe" src="data/img6.png" width="300" height="75" alt="Image result for canadian cardiovascular society"/></div><div id="spr7_52e6ccbe" style="left:3.349px;top:509.906px;"><div style="width:0px;"><span id="txt3_52e6ccbe" class="nokern" data-width="618.160156" style="left:9.321px;top:6.162px;">Anderson et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Canadian Journal of Cardiology 2016;32:1263-1282</span></div></div><div id="spr8_52e6ccbe" style="left:3.349px;top:509.906px;"><div style="width:0px;"><span id="txt4_52e6ccbe" class="nokern" data-width="618.160156" style="left:7.2px;top:4.041px;">Anderson et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Canadian Journal of Cardiology 2016;32:1263-1282</span></div></div><div id="spr9_52e6ccbe" style="left:19.805px;top:150.701px;"><div style="width:0px;"><span id="txt5_52e6ccbe" class="nokern relpos" style="left:7.2px;top:5.317px;"></span><span id="txt6_52e6ccbe" class="relpos" data-width="601.680664" style="left:24.135px;top:4.812px;">We suggest the use of PCSK9 inhibitors (evolocumab, alirocumab) to lower</span></div><div style="width:0px;"><span id="txt7_52e6ccbe" data-width="635.744141" style="left:34.2px;top:31.212px;">LDL-C for patients with heterozygous familial hypercholesterolemia whose LDL-</span></div><div style="width:0px;"><span id="txt8_52e6ccbe" class="relpos" data-width="524.498047" style="left:34.2px;top:57.612px;">C remains above target despite maximally tolerated statin therapy</span><span id="txt9_52e6ccbe" class="relpos" style="left:34.195px;top:57.612px;"> </span><span id="txt10_52e6ccbe" class="relpos" style="left:34.19px;top:63.143px;">(</span><span id="txt11_52e6ccbe" class="relpos" data-width="71.185005" style="left:34.185px;top:63.261px;">Conditional</span></div><div style="width:0px;"><span id="txt12_52e6ccbe" class="relpos" data-width="263.536560" style="left:34.2px;top:83.799px;">recommendation, moderate quality evidence</span><span id="txt13_52e6ccbe" class="relpos" style="left:34.195px;top:83.682px;">)</span></div><div style="width:0px;"><span id="txt14_52e6ccbe" class="nokern relpos" style="left:7.2px;top:132.517px;"></span><span id="txt15_52e6ccbe" class="relpos" data-width="614.732422" style="left:24.135px;top:132.012px;"> We suggest that PCSK9 inhibitors be considered to lower LDL-C for patients</span></div><div style="width:0px;"><span id="txt16_52e6ccbe" data-width="620.780273" style="left:34.2px;top:158.412px;">with atherosclerotic cardiovascular disease in those not at LDL-C goal despite</span></div><div style="width:0px;"><span id="txt17_52e6ccbe" class="relpos" data-width="382.583008" style="left:34.2px;top:184.812px;">maximally tolerated statin +/- ezetimibe therapy </span><span id="txt18_52e6ccbe" class="relpos" data-width="239.442810" style="left:34.195px;top:190.461px;">(Conditional recommendation, moderate</span></div><div style="width:0px;"><span id="txt19_52e6ccbe" data-width="103.802193" style="left:34.2px;top:210.976px;">quality evidence)</span></div><div style="width:0px;"><span id="txt20_52e6ccbe" class="nokern relpos" style="left:7.2px;top:259.717px;"></span><span id="txt21_52e6ccbe" class="relpos" data-width="621.875977" style="left:24.135px;top:259.212px;">We suggest that evolocumab be added to background therapy in patients with</span></div><div style="width:0px;"><span id="txt22_52e6ccbe" data-width="619.727539" style="left:34.2px;top:285.612px;">homozygous familial hypercholesterolemia and continued if LDL-C lowering is</span></div><div style="width:0px;"><span id="txt23_52e6ccbe" class="relpos" data-width="104.317383" style="left:34.2px;top:312.012px;">documented </span><span id="txt24_52e6ccbe" class="relpos" data-width="341.559998" style="left:34.195px;top:317.661px;">(Conditional recommendation, moderate quality evidence)</span></div></div></div></div>');})();